Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART19 cells |
Synonyms | |
Therapy Description |
CART19 cells are allogeneic T lymphocytes engineered to express a CD19-targeted chimeric antigen receptor (CAR) containing a CD3 zeta chain and the TNFRSF9 (4-1BB) signaling domain, which may induce antitumor activity (PMID: 21716851). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART19 cells | CART-19 cells | CD19 Immune Cell Therapy 62 | CART19 cells are allogeneic T lymphocytes engineered to express a CD19-targeted chimeric antigen receptor (CAR) containing a CD3 zeta chain and the TNFRSF9 (4-1BB) signaling domain, which may induce antitumor activity (PMID: 21716851). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02640209 | Phase I | CART19 cells | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | Terminated | USA | 0 |
NCT02935543 | Phase II | CART19 cells | CART19 in Patient With ALL | Terminated | USA | 0 |